Bavituximab

OncXerna Therapeutics Announces Final Results and New Xerna™ TME Panel Biomarker Data from a Phase 2 Trial of Bavituximab Plus Pembrolizumab in Patients with Previously Untreated Advanced Hepatocellular Carcinoma

Retrieved on: 
Monday, January 23, 2023

WALTHAM, Mass., Jan. 23, 2023 (GLOBE NEWSWIRE) -- OncXerna Therapeutics, Inc. (“OncXerna”), a precision medicine company using an innovative RNA expression-based biomarker platform to predict patient responses to its targeted oncology therapeutic candidates, announced final results from a Phase 2 trial of bavituximab plus pembrolizumab in patients with previously untreated advanced hepatocellular carcinoma and new biomarker data demonstrating that the Xerna™ TME Panel clearly identified trial participants more likely to benefit from treatment. The data were featured in a poster that was presented on January 20, 2023 at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI).

Key Points: 
  • WALTHAM, Mass., Jan. 23, 2023 (GLOBE NEWSWIRE) -- OncXerna Therapeutics, Inc. (“OncXerna”), a precision medicine company using an innovative RNA expression-based biomarker platform to predict patient responses to its targeted oncology therapeutic candidates, announced final results from a Phase 2 trial of bavituximab plus pembrolizumab in patients with previously untreated advanced hepatocellular carcinoma and new biomarker data demonstrating that the Xerna™ TME Panel clearly identified trial participants more likely to benefit from treatment.
  • The data were featured in a poster that was presented on January 20, 2023 at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI).
  • The biomarker results presented at ASCO GI are from a planned analysis of tumor biopsies using the Xerna TME Panel, a novel RNA expression-based diagnostic panel that uses a machine learning-based algorithm to classify patients based on the interplay between angiogenic and immunogenic dominant biologies of the tumor microenvironment (TME).
  • The high response rate seen in these patients is rarely achieved in this challenging disease.

OncXerna Therapeutics Doses First Patient in Phase 2 Trial Evaluating Navicixizumab Alone or in Combination with Chemotherapy in Patients with Select Advanced Solid Tumors

Retrieved on: 
Thursday, September 8, 2022

WALTHAM, Mass., Sept. 08, 2022 (GLOBE NEWSWIRE) -- OncXerna Therapeutics, Inc. (“OncXerna”), a precision medicine company using an innovative RNA expression-based biomarker platform to predict patient responses to its targeted oncology therapeutic candidates, today announced the initiation of dosing in a Phase 2 basket trial evaluating the anti-DLL4/VEGF bispecific antibody navicixizumab, alone or in combination with chemotherapy, in patients with select advanced solid tumors.

Key Points: 
  • The colorectal cancer cohort is evaluating navicixizumab alone and in combination with irinotecan, while the triple negative breast cancer cohort is evaluating navicixizumab alone and in combination with paclitaxel.
  • The relationship between TME subtypes and the anti-tumor activity of studied regimens will be evaluated as a secondary endpoint in the trial.
  • Aberrant Notch expression is associated with poor prognosis and treatment resistance in many solid tumors, including colorectal cancer and triple-negative breast cancer.
  • OncXerna Therapeutics is a clinical stage precision medicine oncology company developing novel therapies to treat solid tumors.

Global Targeted Drug Delivery Market Share, Outlook, and Opportunity Analysis, 2022-2030 - ResearchAndMarkets.com

Retrieved on: 
Thursday, June 16, 2022

The "Global Targeted Drug Delivery Market by Disease Type, Application, End-user, and Region - Size, Share, Outlook, and Opportunity Analysis, 2022-2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Targeted Drug Delivery Market by Disease Type, Application, End-user, and Region - Size, Share, Outlook, and Opportunity Analysis, 2022-2030" report has been added to ResearchAndMarkets.com's offering.
  • Targeted drug delivery is the selective transport of drug to targeted tissues, organs, and cells through various drug carriers.
  • Targeted drug delivery is designed to improve the pharmacological and therapeutic properties of conventional drugs and to overcome problems, such as limited solubility, drug aggregation, poor bio-distribution, and lack of selectivity, control drug release carrier, and reduce normal tissue damage.
  • There are different types of drug delivery vehicles, such as polymeric micelles, liposomes, lipoprotein-based drug carriers, nanoparticle drug carriers, and dendrimers.

OncXerna Therapeutics Announces Upcoming ASCO Poster Featuring Data Showing the Phase 2 Glioblastoma Trial of Bavituximab with Chemoradiation and Adjuvant Temozolomide Met its Primary Endpoint

Retrieved on: 
Friday, June 3, 2022

WALTHAM, Mass., June 03, 2022 (GLOBE NEWSWIRE) -- OncXerna Therapeutics, Inc. (“OncXerna”), a precision medicine company using an innovative RNA-expression based biomarker platform to predict patient responses to its targeted oncology therapeutic candidates, today announced new clinical data from an investigator-sponsored Phase 2 trial evaluating bavituximab combined with chemoradiation and adjuvant temozolomide in newly diagnosed glioblastoma (GBM) patients. The data, which show that the trial met its primary endpoint, will be featured in a poster at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting taking place both virtually and in-person at the McCormick Place Convention Center in Chicago, Illinois.

Key Points: 
  • The Phase 2 results being presented at ASCO suggest bavituximab modulates the immunosuppressive GBM microenvironment, demonstrating its on-target effects.
  • We look forward to discussing these latest Phase 2 data with key thought leaders as we assess next steps for bavituximab in GBM.
  • The Phase 2 trial was an open-label, single-arm study designed to evaluate the safety and efficacy of bavituximab with chemoradiation and adjuvant temozolomide in adult patients with newly diagnosed glioblastoma.
  • The trial included 33 evaluable patients who were treated with bavituximab weekly, temozolomide daily, and chemoradiotherapy in accordance with hospital guidance.

OncXerna Therapeutics Announces Journal of Clinical Oncology Publication Featuring Phase 1b Data of Navicixizumab Plus Paclitaxel in Ovarian Cancer

Retrieved on: 
Thursday, April 21, 2022

WALTHAM, Mass., April 21, 2022 (GLOBE NEWSWIRE) -- OncXerna Therapeutics, Inc. (“OncXerna”), a precision medicine company using an innovative RNA-expression based biomarker platform to predict patient responses to its targeted oncology therapeutic candidates, today announced the peer-reviewed publication of results from a Phase 1b trial evaluating navicixizumab, an anti-DLL4/VEGF bispecific antibody, combined with paclitaxel, in patients with platinum-resistant ovarian cancer (PROC). The paper, entitled, “Phase Ib Study of Navicixizumab Plus Paclitaxel in Patients With Platinum-Resistant Ovarian, Primary Peritoneal, or Fallopian Tube Cancer,” was published in Journal of Clinical Oncology and can be found here.

Key Points: 
  • The paper, entitled, Phase Ib Study of Navicixizumab Plus Paclitaxel in Patients With Platinum-Resistant Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, was published in Journal of Clinical Oncology and can be found here .
  • The Phase 1b trial was an open-label, non-randomized, dose-escalation and expansion study of the safety, tolerability, and efficacy of navicixizumab plus paclitaxel in patients with platinum-resistant ovarian cancer.
  • Navicixizumab is an anti-DLL4/VEGF bispecific antibody product candidate that demonstrated antitumor activity in patients who were previously treated with Avastin (bevacizumab) in a Phase 1b clinical trial.
  • OncXerna Therapeutics is a clinical stage oncology company developing novel monoclonal antibodies to treat solid tumors.

OncXerna Therapeutics Highlights the Xerna™ TME Panel’s Prognostic and Predictive Value Across Indications and Therapeutic Classes at the AACR Annual Meeting

Retrieved on: 
Monday, April 11, 2022

WALTHAM, Mass., April 11, 2022 (GLOBE NEWSWIRE) -- OncXerna Therapeutics, Inc. (“OncXerna”) is a precision medicine company using an innovative RNA-expression based biomarker platform to predict patient responses to its targeted oncology therapeutic candidates. Today the company announced biomarker data demonstrating the Xerna TME Panel’s prognostic value across multiple indications in a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting. Data also suggest the potential for Xerna TME Panel to predict patients most likely to benefit from immune- and angiogenic-targeted therapy.

Key Points: 
  • Today the company announced biomarker data demonstrating the Xerna TME Panels prognostic value across multiple indications in a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting.
  • Data also suggest the potential for Xerna TME Panel to predict patients most likely to benefit from immune- and angiogenic-targeted therapy.
  • RNA expression signatures to predict therapeutic response have struggled with defining thresholds that clearly distinguish patients more likely to benefit from those that are not.
  • "Using artificial intelligence, we have been able to unlock the potential of RNA-based expression gene signatures, said Laura Benjamin, CEO of OncXerna Therapeutics.

OncXerna Therapeutics to Present at Jefferies Virtual Healthcare Conference

Retrieved on: 
Tuesday, May 18, 2021

b'WALTHAM, Mass., May 18, 2021 (GLOBE NEWSWIRE) -- OncXerna Therapeutics, Inc., a precision medicine company using an innovative RNA-expression based biomarker platform to predict patient responses to its first-in-class targeted oncology therapies, today announced that Laura Benjamin, Ph.D., Founder and CEO of OncXerna, will present at the Jefferies Virtual Healthcare Conference taking place June 1-4, 2021.\nThe live presentation will occur on June 4, 2021 from 10:30 a.m. to 10:55 a.m.

Key Points: 
  • b'WALTHAM, Mass., May 18, 2021 (GLOBE NEWSWIRE) -- OncXerna Therapeutics, Inc., a precision medicine company using an innovative RNA-expression based biomarker platform to predict patient responses to its first-in-class targeted oncology therapies, today announced that Laura Benjamin, Ph.D., Founder and CEO of OncXerna, will present at the Jefferies Virtual Healthcare Conference taking place June 1-4, 2021.\nThe live presentation will occur on June 4, 2021 from 10:30 a.m. to 10:55 a.m.
  • This allows OncXerna to pair those patients with OncXerna\xe2\x80\x99s clinical-stage therapies and known mechanism of action that directly address these biologies, to dramatically improve patient outcomes.
  • OncXerna is targeting patients whose dominant tumor biology is driven by angiogenesis with a focus beyond VEGF to include broader anti-angiogenic pathways.
  • OncXerna\xe2\x80\x99s clinical trials currently combine bavituximab with KEYTRUDA\xc2\xae to test the hypothesis that relieving immunosuppression can enhance responses to checkpoint inhibitors.

OncXerna Therapeutics Provides New Results from its Xerna™ RNA-based Biomarker Platform at the AACR Annual Meeting

Retrieved on: 
Saturday, April 10, 2021

In this study, OncXerna demonstrated that the first panel (TME Panel) from its Xerna platform revealed prognostic subtypes in colorectal cancer (CRC) by analyzing tumor samples from over 600 CRC patients.

Key Points: 
  • In this study, OncXerna demonstrated that the first panel (TME Panel) from its Xerna platform revealed prognostic subtypes in colorectal cancer (CRC) by analyzing tumor samples from over 600 CRC patients.
  • In our AACR presentation, we presented results that verify the capabilities of our TME Panel and enable its expanded use for patients with colorectal cancer.
  • These exciting findings pave the way for future prospectively-driven trials with the Xerna TME Panel and our clinical-stage programs, navicixizumab and bavituximab.
  • About OncXerna Therapeutics, its Xerna RNA-based Biomarker Platform, and Xerna TME Panel
    OncXerna plans to deliver next-generation precision medicine to a larger group of cancer patients by leveraging the companys Xerna platform to prospectively identify patients based on the dominant biology of their cancer.

Oncologie Announces First Patient Enrolled in Global Phase 2 Study of Bavituximab Plus KEYTRUDA® (Pembrolizumab) for Advanced Gastric or Gastroesophageal Cancer

Retrieved on: 
Wednesday, October 9, 2019

Oncologie is collaborating with MSD in this clinical study to evaluate the combination of bavituximab and KEYTRUDA in patients with advanced gastric or gastroesophageal cancer.

Key Points: 
  • Oncologie is collaborating with MSD in this clinical study to evaluate the combination of bavituximab and KEYTRUDA in patients with advanced gastric or gastroesophageal cancer.
  • The rationale to support this study was based on a previously reported retrospective analysis from over 90 patients who were enrolled in a Phase 3 lung cancer study, which demonstrated activity when Bavituximab was given prior to a PD-1 inhibitor.
  • "This Phase 2 study is intended to further evaluate the antitumor activity and safety of bavituximab plus pembrolizumab in a gastric cancer population.
  • Headquartered in Boston, Massachusetts and Shanghai, China, Oncologie is working with global partners to acquire and develop innovative drugs for cancer patients around the world.